Reduced sick leave in multiple sclerosis after one year of natalizumab treatment



This post-hoc analysis assessed the amount of sick leave in patients with RRMS before and one year after treatment with natalizumab and correlated the sick leave to fatigue and walking ability, using data from the Capacity for Work Questionnaire (CWQ) obtained in the TYNERGY trial.

Results from this analysis demonstrated that there was a reduction in sickness benefit by an absolute change of 33% after one year of treatment with natalizumab. The reduction in sick leave was significantly associated with younger age and improvement of walking ability.

Therefore, these results demonstrate a positive association between natalizumab therapy and an improvement in work ability.

Authors:Wickström A, Dahle C

Source: Mult Scler. 2013 Dec 30. [Epub ahead of print]
Read the abstract




 

Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial